German radiopharmaceutical group ITM Isotopen Technologien München has signed supply agreements with radiopharmaceutical Point Biopharma for ITM's EndolucinBeta (no-carrier-added lutetium-177) radiopharmaceutical precursor.
The two deals will support the clinical and commercial supply of PNT2002, a radiopharmaceutical candidate for the treatment of metastatic castrate-resistant prostate cancer. The first contract details a partnership for the clinical development of PNT2002, while the second is a long-term commercial agreement for the supply of no-carrier-added lutetium-177 following the marketing approval of PNT2002.
A phase III clinical trial for PNT2002 is expected to begin enrolling patients in the fourth quarter, according to the companies. Further terms of the deals were not disclosed.
![A 53-year-old patient (patient number four) with a recurrent pituitary adenoma with extension of a cystic component of disease to the medial temporal lobe apparent on MRI (contoured in blue), and extension of disease to the left sphenoid bone and orbital apex apparent on [68Ga]Ga-DOTA-TATE (contoured in yellow).](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/04/pituitary-tumor.QGsEnyB4bU.jpg?auto=format%2Ccompress&fit=crop&h=100&q=70&w=100)
![A 53-year-old patient (patient number four) with a recurrent pituitary adenoma with extension of a cystic component of disease to the medial temporal lobe apparent on MRI (contoured in blue), and extension of disease to the left sphenoid bone and orbital apex apparent on [68Ga]Ga-DOTA-TATE (contoured in yellow).](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/04/pituitary-tumor.QGsEnyB4bU.jpg?auto=format%2Ccompress&dpr=2&fit=crop&h=167&q=70&w=250)
